MedTrace Logo

A Relative Bioavailability Study of Fentanyl 25 μg/h Transdermal System

NCT00864565 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2010-08-16

No results posted yet for this study

Summary

To compare the rate and extent of absorption of fentanyl 25 μg/h transdermal system (test) and Duragesic (reference) administrated as 1 x 25 μg/h single transdermal system application.

Conditions

  • Healthy

Interventions

DRUG

Fentanyl 25 μg/h transdermal system, single application

A: Experimental Subjects received Corium International, Inc formulated products

DRUG

Duragesic 25 μg/h transdermal system single application

B: Active comparator Subjects received Jassen Pharmaceutica Products, L.P. formulated products

Sponsors & Collaborators

  • Actavis Inc.

    lead INDUSTRY

Principal Investigators

  • Benoit Girard · Anapharm

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2003-06-30
Completion
2003-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00864565 on ClinicalTrials.gov